Astellas Wins Additional U.S. Indications For Antifungal Mycamine
This article was originally published in PharmAsia News
Executive Summary
Astellas Pharma gained U.S. FDA approval of four new indications for its antifungal Mycamine (micafungin), the firm announced Jan. 22
You may also be interested in...
Astellas Tacrolimus Approval Remains At Bay
Astellas Pharma has met with another snag in its attempt to win FDA approval for the once-daily version of its immunosuppressant Prograf (tacrolimus) with receipt of an FDA "approvable" letter for prophylaxis of organ rejection in liver transplant patients
Astellas Tacrolimus Approval Remains At Bay
Astellas Pharma has met with another snag in its attempt to win FDA approval for the once-daily version of its immunosuppressant Prograf (tacrolimus) with receipt of an FDA "approvable" letter for prophylaxis of organ rejection in liver transplant patients
EMEA Recommends Approval For Astellas’ Mycamine
PERTH, Australia - The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended that Astellas Pharma's antifungal Mycamine (micafungin) be approved for candidiasis, Astellas announced Feb. 21